Xi Yu-Jia, Wen Rui, Zhang Ran, Dong Qi-Rui, Zhang He-Yi, Su Qin-Yi, Zhang Sheng-Xiao
Department of Urology, Second Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, P.R. China.
Shanxi Provincial Key Laboratory of Rheumatism Immune Microecology, Shanxi Province, Taiyuan, P.R. China.
Basic Clin Androl. 2023 Jul 6;33(1):18. doi: 10.1186/s12610-023-00192-0.
As one of the most critical proteins in the JAK/STAT signaling pathway, Janus kinase 2 (JAK2) is involved in many biological processes and diseases. Several observational studies have reported the role of JAK2 in erectile dysfunction. However, the causal relationship between JAK2 and erectile dysfunction remains unclear. Here we investigated the causal relationship between JAK2 and erectile dysfunction.
Genetically predicted JAK2 was causally associated with erectile dysfunction in inverse variance weighting (OR = 1.109, 95% CI = 1.029-1.196, p = 0.007) and weighted median method (OR = 1.117, 95% CI = 1.003-1.245, p = 0.044). No heterogeneity was observed in Cochran Q-test (p = 0.855) and MR-PRESSO (p = 0.866). Pleiotropy was not observed in our study (p = 0.617).
These findings highlighted JAK2 as a risk factor for erectile dysfunction and proved the causal relationship between JAK2 and erectile dysfunction, suggesting that targeting JAK2 signaling might be a novel and promising therapeutic candidate in the treatment of erectile dysfunction.
作为JAK/STAT信号通路中最关键的蛋白之一，Janus激酶2（JAK2）参与许多生物学过程及疾病。多项观察性研究报道了JAK2在勃起功能障碍中的作用。然而，JAK2与勃起功能障碍之间的因果关系仍不明确。在此我们研究了JAK2与勃起功能障碍之间的因果关系。
在逆方差加权法（OR = 1.109，95%置信区间 = 1.029 - 1.196，p = 0.007）和加权中位数法（OR = 1.117，95%置信区间 = 1.003 - 1.245，p = 0.044）中，基因预测的JAK2与勃起功能障碍存在因果关联。在Cochran Q检验（p = 0.855）和MR-PRESSO（p = 0.866）中未观察到异质性。在我们的研究中未观察到多效性（p = 0.617）。
这些发现突出了JAK2作为勃起功能障碍的一个风险因素，并证明了JAK2与勃起功能障碍之间的因果关系，表明靶向JAK2信号通路可能是治疗勃起功能障碍的一种新的且有前景的治疗选择。
